Last reviewed · How we verify
Salbutamol HFA-134a
Salbutamol HFA-134a is a Beta-2 adrenergic agonist (short-acting) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Acute bronchospasm and reversible airway obstruction in asthma, Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction.
Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.
Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation. Used for Acute bronchospasm and reversible airway obstruction in asthma, Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction.
At a glance
| Generic name | Salbutamol HFA-134a |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Beta-2 adrenergic agonist (short-acting) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Salbutamol activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering increased intracellular cAMP levels and smooth muscle relaxation. This leads to rapid airway dilation and relief of bronchoconstriction. The HFA-134a formulation refers to the hydrofluoroalkane propellant used in the metered-dose inhaler.
Approved indications
- Acute bronchospasm and reversible airway obstruction in asthma
- Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma (PHASE3)
- A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive (PHASE1)
- A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive (PHASE1)
- Advair HFA in Healthy and HAPE Predisposed Subjects (PHASE1, PHASE2)
- Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype (EARLY_PHASE1)
- Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants (PHASE1)
- Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) (PHASE3)
- Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salbutamol HFA-134a CI brief — competitive landscape report
- Salbutamol HFA-134a updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Salbutamol HFA-134a
What is Salbutamol HFA-134a?
How does Salbutamol HFA-134a work?
What is Salbutamol HFA-134a used for?
Who makes Salbutamol HFA-134a?
What drug class is Salbutamol HFA-134a in?
What development phase is Salbutamol HFA-134a in?
What are the side effects of Salbutamol HFA-134a?
What does Salbutamol HFA-134a target?
Related
- Drug class: All Beta-2 adrenergic agonist (short-acting) drugs
- Target: All drugs targeting Beta-2 adrenergic receptor (ADRB2)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Acute bronchospasm and reversible airway obstruction in asthma
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction
- Compare: Salbutamol HFA-134a vs similar drugs
- Pricing: Salbutamol HFA-134a cost, discount & access